Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS
· Delayed Price · Currency is USD
2.360
0.00 (0.00%)
Jun 18, 2025, 4:00 PM EDT
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $129.39K in the quarter ending March 31, 2025, a decrease of -11.30%. This brings the company's revenue in the last twelve months to $519.87K, up 8.88% year-over-year. In the year 2024, Lipella Pharmaceuticals had annual revenue of $536.36K with 19.29% growth.
Revenue (ttm)
519.87K
Revenue Growth
+8.88%
P/S Ratio
14.18
Revenue / Employee
86.64K
Employees
7
Market Cap
7.37M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Lipella Pharmaceuticals News
- 2 days ago - Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewsWire
- 5 days ago - Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewsWire
- 2 months ago - Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” - GlobeNewsWire
- 3 months ago - Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewsWire
- 3 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - GlobeNewsWire
- 4 months ago - Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Benzinga
- 4 months ago - Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewsWire
- 5 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - GlobeNewsWire